Irinotecan pharmacogenomincs: A single sample observational study
Patients may be receiving irinotecan as montherapy or as part of a combination regimen. This is an observational study requiring only a single blood sample from patients already scheduled to receive irinotecan. The blood sampling will be obtained in the chemotherapy suite immediately following the end of the irinotecan infusion from the opposite arm (and be drawn into a tube containing heparin). The blood sample is to be delivered to the core lab facility at Victoria Hospital for transfer (via inter hospital courier) to University Hospital Core facility on ice (No processing required at Victoria Hospital).
See Trial Summary.
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society